Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Billionaire Larry Robbins Added These Stocks to Glenview’s Portfolio in Q2

Page 1 of 2

Billionaire Larry Robbins founded Glenview Capital in 2001 after having been previously employed as a trader at Leon Cooperman’s Omega Advisors. Currently, Glenview has offices in New York City and London and employs a Growth at a Reasonable Price strategy, also known as GARP. The fund focuses on companies that generate recurring revenues.

The equity value of Glenview’s portfolio totaled $14.14 billion at the end of the second quarter, according to the firm’s last 13F filing. The fund had the biggest exposure to the healthcare sector, which accounted for 57% of the total holdings and 14% of the portfolio was invested in the materials sector at the end of the second quarter. In this article, we will look at some of Glenview’s largest new positions initiated during the second quarter.

Out of thousands of stocks that are trading on the market every day, it can be difficult sometimes to pick the right investment that can deliver market-beating returns. Here’s where our research comes in. By analyzing the equity portfolios of over 740 top investors, we can see what stocks they are collectively bullish on and use this data to compile a portfolio that can outperform the market. We have determined through this process that the best strategy is to follow the 15 most popular small-cap picks among hedge funds, which have delivered an alpha of around 81 basis points per month in our backtests covering the period between 1999 and 2012 (see more details).

GLENVIEW CAPITAL

In IMS Health Holdings Inc (NYSE:IMS), Glenview  acquired 6.76 million shares of IMS Health during the quarter, the market value of which stood at $171.41 million at the end of June. Overall, 21 funds in our database were long IMS Health at the end of the second quarter, holding $892.48 million worth of shares, amassing 10.70% of the total outstanding shares. The number of funds from our database holding shares of IMS Health at the end of the first quarter stood at 23, while the total value of their holdings amounted to $631.95 million. IMS Health recently announced that it plans to raise $1.5 billion through a debt offering. The company will issue senior notes due 2024 in two separate tranches, in U.S. dollars and Euros. IMS Health plans to use the net proceeds from the offering, along with some existing cash and additional term loans, to retire certain debt associated with the Quintiles Transnational Holdings Inc (NYSE:Q) merger.

Follow Ims Health Holdings Inc. (NYSE:IMS)
Trade (NYSE:IMS) Now!

Glenview Capital bought 7.13 million shares of Williams Companies Inc. (NYSE:WMB) during the second quarter, which were valued at $154.28 million at the end of the quarter. The number of funds long Williams Companies went up to 58 from 52 during the second quarter, while the total value of their holdings advanced to $3.63 billion from $2.27 billion worth of shares at the end of the previous quarter. Recently, Keith Meister, an activist investor and manager of Corvex Management, issued a letter sent to three new board members of Williams Companies Inc. (NYSE:WMB), in which he urged them to create a strategic review committee among themselves in order to assess the benefits of a merger with Enterprise Products Partners and other companies in the industry, among other things.

Follow Williams Companies Inc (NYSE:WMB)
Trade (NYSE:WMB) Now!

Read about Glenview Capital’s three other new positions on the next page.

Page 1 of 2
Loading Comments...